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Background: Acute lymphoblastic leukemia (ALL) is a heterogeneous group of 
lymphoid neoplasms resulting from the proliferation of malignant lymphoid cells. 
The aim of this study was to evaluate treatment-related complications in children 
with ALL receiving the Medical Research Council (MRC) UKALL X protocol.  
Methods: In this retrospective cross-sectional study, children with ALL receiving 
the MRC UKALL X protocol from 2008 to 2015 in Bahrami University Hospital, 
Iran, were enrolled. The clinical and morphological features were analysed and 
treatment-related complications were assessed.  
Results: Out of 67 children with ALL receiving the MRC UKALL X protocol, 44 
(65.6 %) were boys and 23 (34.4%) were girls. Seven patients (10.7%) relapsed in 
the three years of diagnosis, and 50 children (74.6%) had an overall survival of three 
years. Average age in three-year-survival group and mortality group was 6.92 (SD: 
3.96) and 6.35 (SD: 7.47), respectively (P= 0.38).  
Conclusion: Overall survival and relapse rates in this study confirm that this 
protocol is an appropriate treatment strategy. 
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Introduction 
Acute lymphoblastic leukemia (ALL) is a 
heterogeneous group of lymphoid neoplasms 
resulting from monoclonal proliferation of 
malignant lymphoid cells in the blood, bone 
marrow, and other organs.1 ALL accounts for 
25% of childhood malignancy with an annual 
incidence rate of 3 to 4 cases per 100 000 children 
under 15 years of age.2, 3 Nowadays, owing to 
intensive chemotherapy methods, the outcomes 
of ALL  have significantly improved and the 
complete response rate is about 80%.4 Over the 
past five decades, the outcome of childhood ALL 
has evolved from a median survival of two months 
to a long-term survival rate.5 Substantially, since 
1970, intensified treatment protocols have been 
introduced via the UK Medical Research Council 
(MRC) in accordance with the risk stratification 
of children in all risk groups.6 UK-ALL Χ protocol 
has been made of vincristine, prednisolone, 
daunorubicin, and asparaginase (6000 IU/m2 
3×week×9) identical to UKALL VIIIB along with 
intrathecal methotrexate on days 1, 15, and 29.7 
Despite dramatic survival improvement (roughly 
5-year overall survival (OS)) following intensive 
consolidation therapy, relapse is the leading cause 
of treatment failure in 15-20% of patients.2,8 
Moreover, the survival rate following relapse is 
still partly low.9 Furthermore, contemporary 
implementation of intensification therapy entails 
mild to severe complications in patients and the 
frequency of treatment-related mortality is 
reported to be 2-4%.10,11 In addition, the most 
life-threatening complications of prolonged 
treatment protocol are febrile neutropenia and 
infection in children with ALL.11,12 
Therefore, the outcomes in children treated 
by the MRC UKALL X trial were analysed in 
order to evaluate the complications of the 
treatment protocol in childhood ALL in the hope 
of finding effective strategies to reduce the 
treatment-related mortality and morbidity. 
 
Materials and Methods 
This is a retrospective study conducted at 
Bahrami University Hospital, Iran on children 
with ALL between 2008 and 2015. After receiving 
the ethics approval by Tehran University of 
Medical Sciences and informed consent, patients' 
demographic data and clinical characteristics, 
including age, gender, ALL morphology subtype, 
WBC, and neutrophil counts, Hb level and 
outcome-before and after every session of 
consolidation treatment and also in the interval 
between occurrences-were collected with the 
standard available data sheets. 
 
Neutropenia 
Criteria for the diagnosis of treatment-related 
neutropenia were described as the reduction in 
neutrophil counts appearing from the onset of 
treatment until 30 days.  
 
Ethical consideration 
This research study followed the tenets of the 
Declaration of Helsinki and written informed 
consent was obtained from all patients. The study 




Data were analysed using statistical package 
for the social sciences (SPSS) version 16 (SPSS 
Inc. Chicago, IL) for windows. Data were 
presented as mean/median values and percentages. 
Cox-proportional hazard model was employed 
for multivariate analysis. 
 
Results 
A total of 75 children with ALL were 
examined, 67 of whom were treated by UKALL 
X trial. The mean age of patients was 6.78 years 
(1.5 months to 15 years, Mod: 5, SD: 4.148). 
Table1 shows patient demographic data and 
clinical characteristics. The preponderance of 
males was in relapsed and expired groups, 
implying the common referral pattern in Iran. 
Due to the abnormal distribution of patient 
population, independent non-parametric test was 
utilized to investigate the relationship between 
mortality and age. The average age in three-year-
survival group and mortality group was 6.92 (SD: 
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3.96) and 6.35 (SD: 7.47), respectively. (P= 0.38)  
Thirty-two patients received consolidation 
therapy, 35 patients received second-line therapy, 
and 23 cases completed both stages. 
Data on WBC and neutrophil counts and 
hemoglobin level prior to the onset of treatment 
were recorded for both consolidation and second-
line therapy. These data were further recorded in 
cases of hospitalization for neutropenia and at 
the time of discharge. 
Neutropenia appeared approximately 12 days 
(SD: 2.66) and 12.63 days (SD: 4.83) after 
consolidation and second-line therapy, 
respectively.  
Among 33 patients receiving consolidation 
therapy, 17 cases (51.5%) showed neutropenia, 
which also was the case with 19 patients from 
all 35 subjects who had received second-line 
therapy. No neutropenia-related mortality was 
reported following consolidation therapy.   
Mean duration of hospitalization subsequent 
to consolidation in all patients and  the neutropenic 
group was 4.8 (SD: 4.032) and 7.47 days (SD: 
2.183), respectively. Concerning second-line 
therapy, duration of hospitalization was 5.51 (SD: 
6.161) and 10.6 days (4.682) in all patients and 
in neutropenic cases, respectively.  
Further evaluation was the association between 
neutropenia after each phase of consolidation 
therapy and the age of patients. In the first phase, 
the mean age was 6.59 (SD: 4.22) and 6.72 years 
(SD: 3.61) for neutropenic and non-neutropenic 
patients, respectively (P value= 0.8) (Mann–
Whitney U = 129.000).  
For the second cycle of consolidation therapy, 
the mean age of neutropenic and non-neutropenic 
patients was 6.58 (SD: 4.36) and 6.81 years (SD: 
3.31), respectively (Mann–Whitney U = 137.000). 
 
Discussion 
This retrospective analysis focused on 
treatment-related complications in children with 
ALL receiving the MRC UKALL X protocol. 
Similar to previous reports, higher incidence in 
males (~ 65%) and in the age group of 0-5 years 
was observed in the population study. No obvious 
differences were seen regarding morphology 
incidence in contrast to previous studies, hence 
the possible necessity of a larger sample size.  
Neutropenia is one of the significant 
complications of chemotherapy in ALL patients, 
making them susceptible to a variety of infections. 
The duration of treatment-induced neutropenia 
is assumed to be the most important risk factor 
for infections in pediatric malignancies. It is also 
to be noted some studies have suggested that 
neutropenia is not the only risk factor in the 
development of infectious complications during 
chemotherapy.13 There are few reports on 
infectious morbidity rates in childhood ALL in 
Iran. 
In a recent study, treatment-induced 
neutropenia was considered as a neutropenia 
presenting during the first month of treatment. 
In the first three years of the disease, 89.5% 
of the patients were hospitalized due to 
neutropenia and fever, with the mean of 
neutropenia duration being 29.32 days. In another 
study, a higher incidence of fever, infection, and 
neutropenia and a higher frequency of antibacterial 
therapy were found in patients under 2.5 years, 
compared with the older groups.14 In 2000, Namic 
Ozbek et al. compared the effects of three different 
treatments, namely granulocyte-colony stimulating 
factor (G-CSF), high dose methylprednisolone 
(HDMP), and G-CSF combined with HDMP, in 
neutropenic patients on maintenance therapy for 
ALL. They concluded that G-CSF may induce 
an increase in peripheral stem cell numbers,  
confirming hematopoietic recovery by the increase 
in IL-3 in patients with chemotherapy-induced 
neutropenia.15 In another study, it was concluded 
that prophylactic G-CSF did not have any effects 
on children with high-risk ALL.16 In 2014, Ting-
Chi Yeh et al. showed that prophylaxis with 
ciprofloxacin and voriconazole or micafungin 
could reduce the rates of bloodstream infection 
and invasive fungal infection (IFI) in children 
with acute leukemia undergoing intensive 
chemotherapy.17 
According to this investigation, the mortality 
percentage was 25.4% (17 cases) in the first three 
years of treatment. Although the findings indicated  
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that the highest mortality rate was observed in 
0-5 years of age (47%) and in boys (21.7%), none 
of them occurred following consolidation therapy. 
Hargrave and his colleagues analysed data from 
all patients entered in the MRC UKALL VIII, X 
and XI trials between 1980-1997 to compare the 
causes of treatment-related mortality (TRM). 
Based on their findings, bacterial and fungal 
infections were the main causes of mortality and 
from the eight deaths associated with the early 
intensification block on the fifth week, three 
patients were under treatment by UKALL X 
protocol.18 
In the study of David O’Connor et al., 117 
cases of all patients under investigation in the 
UKALL 2003 trial passed away due to treatment 
complications. Moreover, sepsis was the most 
common cause of treatment-related mortality 
(TRM),  particularly during neutropenia period 
with the most incidence in girls.19 Moreover, in 
2016, 409 children with newly diagnosed ALL 
were observed and assessed for infection and it 
was concluded  that young age, intensive 
chemotherapy, and no increase in neutrophil count  
following dexamethasone treatment were 
associated with infection-related complications.11 
Based on other studies and the recent findings, it 
can be said that intensive chemotherapy, especially 
that containing dexamethasone is able to treat 
neutropenia, thereby reducing TRM.  
In a recent study, relapse occurred in seven 
patients (10.4%) in the first three years of 
treatment, showing a relatively favourable 
response to therapy in the patients. As a matter 
of fact, there is no assurance to the outcome of 
the 60 other patients being in remission because 
some patients may relapse after three years.  
The Berlin–Frankfurt–Munster (BFM) group 
divided the relapse period into three categories: 
very early (earlier than 18 months from the 
diagnosis), early (later than 18 months from the 
diagnosis and earlier than six months from the 
end of the treatment), and late (later than six 
months from the end of the treatment), and showed 
that late relapse was associated with a good 
prognosis.20 
Table 1. Patient demographics and clinical characteristics 
           No. of patients                    Male                   Female 
All patients       67 44 (65.6%) 23 (34.4S%) 
 
Age 
0-5 28 (41.7%) 
5-10 20 (29.8%) 
10-19 19 (28.3%) 
 
Relapse characteristics  
Time to relapse>3 years 7 (10.4%) 5 (11.36%) 2 (8.3%) 
 
Mortality 17 (25.4%) 12 (27.2%) 5 (21.7%) 
Ages 




ALL subgroups  
L1 45 (67.2%) 
L2 22 (32.8%) 14 (31.8%) 8 (34.7%) 
 
Hospitalization 
(in the first 3 years of 60 (89.5%) 
treatment due to neutropenia) 
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It is well-known that almost all patients 
undergoing remission by the end of induction 
therapy will relapse without further treatment.21 
Allogeneic hematopoietic stem cell transplant 
(HSCT) has proved a relatively safe treatment, 
yet not necessary for all patients as a post-
remission therapy.22 
Ajay Vora et al. showed that event-free survival 
with augmented post-remission therapy was 
significantly more acceptable than that with 
standard therapy owing to the reduced rate of 
relapse. However, the asparaginase and 
intravenous methotrexate used in the augmented 
treatment regimen caused more complications.23 
The challenges of balancing between the efficacy 
and the toxicity of combination therapy in relapsed 
cases are yet to be surmounted. Management of 
relapsed ALL is a medical priority with the aim 
of further improving the outcome of patients.   
Overall, due to the approved fact that late 
relapse is a desirable prognostic factor, one might 
be led to speculate the relative success of this 
protocol in the field of remission, while prior to 
being generalized, these findings must be 
evaluated in a larger population.  
These findings could also be utilized to include 
the data of other countries, whether or not the 
massive and demanding steps of this protocol 
could be taken with similar results.  
Finally, given the three-year survival and non- 
existence of mortality-related neutropenia after 
consolidation therapies and  the low relapse rate, 
this therapeutic protocol can be a  suitable one 
for childhood ALL in Iran.  
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